Sleep activity: Actinography : Patient will wear actinometers on the wrist for 1 year continuously. In the study, MotionWatch 8 actimeters will be used, a class 1 medical device with CE mark (EN ISO 13485:2016 standard).
Ancillary study :
DREEM 3 headband : a subgroup of patients will wear the headband during 2 nights every 3 months.
Questionnaires: The PSQI, EPWORTH, FACIT-F, ISI, and ICSD-3 questionnaires will be completed by patients every 3 months during their follow-up consultation according to the usual management.
The questionnaire by Horne and Ostberg will be completed by the patients only during the inclusion visit.
Study summary
Inflammatory Bowel Diseases (IBD) go through two phases: flare and remission. Prediction of flares and identification of patients in remission but at high risk of flare are a major issue when taking care of IBD patients.
Considering close interactions between sleep, immunity and intestinal inflammation, sleep disorders could be a predictor of flares.
The purpose of this study is to demonstrate that sleep efficacy decreases before IBD flare.
Patients in remission will be assessed for IBD symptoms (activity scores, biological factors) and sleep disorders (actigraphy, DREEM®, questionnaires) during one year.
Eligibility
Sex
ALL
Min age
18 Years
Max age
65 Years
Healthy volunteers
No
Inclusion Criteria:
* Patient over 18 and under 65 years of age.
* Patient with Inflammatory Bowel Disease diagnosed for at least 3 months.
* Patient in remission, for at least 3 months:
1. clinical remission: Harvey-Bradshaw score (HBI) \< 5 for CD and a Mayo score \< 3 for UC
2. and biological remission: absence of objective inflammation defined by CRP \< 5 mg/L and/or fecal calprotectin \< 250 µg/g.
* Patient must sign informed consent form to participate to the study.
* Patient affiliated to or benefiting from a social security plan.
Exclusion Criteria:
* Patient with complications (obstructive symptoms, fistulas or intra-abdominal abscesses in the previous three months).
* Patient with extensive bowel resection (\> 40 cm of small bowel).
* Patient with an ileostomy or colostomy.
* Patient diagnosed with sleep disorders.
* Patient without legal capacity to consent.
* Pregnant, parturient or nursing women.
* Persons deprived of liberty by judicial or administrative decision.
* Persons under psychiatric care.
* Persons admitted to a health or social institution for purposes other than research.
* Persons of full age who are subject to a legal protection measure (guardianship, curators).
Primary outcome measure(s)
rate of relapse — 12 months after baseline For Crohn's disease:
Harvey Bradshaw Index ≥ 5 AND a CRP \> 5 mg/L and/or calprotectin \> 250 µg/g
For ulcerative colitis:
Mayo ≥ 3 AND a CRP \> 5 mg/L and/or calprotectin \> 250 µg/g Sleep efficiency will be measured by actimetry and expressed as a percentage. Sleep efficiency is defined as the ratio of total time spent asleep compared to total time spent in bed. An actinometer will collect one efficiency measurement per night; an average per week will then be calculated from the daily measurements.
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.
